SAGE Therapeutics, Inc.

SAGE Therapeutics, Inc.

SAGE Therapeutics, Inc.

Overview
Date Founded

2010

Headquarters

215 First Street,Cambridge, MA 02142

Type of Company

Public

Employees (Worldwide)

637

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at SAGE Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Director, President & Chief Executive Officer

Chief Financial Officer & Principal Accounting Officer

Senior Vice President, General Counsel, Secretary

Chief Scientific Officer

Chief Research Officer

Chief Medical Officer

Chief Business Officer

Senior Vice President, People & Organizational Strategy

Senior Vice President, Regulatory Affairs & Quality Assurance

Senior Vice President, Technical Operations

Board of Directors

Co-Founder at Third Rock Ventures LLC

Former Senior Vice President, Chief Financial Officer & Treasurer at Alkermes Plc

Co-Founder at Tal Medical, Inc.

President & Chief Executive Officer at Aevi Genomic Medicine, Inc.

Chief Medical Officer at Intel Corp.

Director, President & Chief Executive Officer at SAGE Therapeutics, Inc.

President & Chief Executive Officer at Elucida Oncology, Inc.

Venture Partner at ARCH Venture Partners

President & Chief Executive Officer at UroGen Pharma Ltd.

Paths to SAGE Therapeutics, Inc.
Potential Connections via
Relationship Science
You
SAGE Therapeutics, Inc.
Owners & Shareholders
Details Hidden

JCM offers U.S. equity, global & international equity, fixed income, asset allocation and alternative investment strategies. The firm also offers investment strategies through affiliated investment advisors. The firm seeks to add value versus benchmarks by actively pursuing alpha generation through proprietary fundamental research. They look for companies with misunderstood fundamentals and price dislocations, as well as rapidly growing companies for some equity strategies. For their equity strategies, JCM favors businesses with sustainable above-average earnings growth potential, outstanding free-cash flow generation, recurring revenue and strong profit margins and return on invested capital. The firm's fixed-income research focuses on businesses that have strong or improving balance sheets, improving free-cash flow generation and recurring revenue. They use a proprietary fixed-income risk management tool named Quantum which allows them to view relative value, risk and returns at the portfolio level, individual credit level and across the investable credit universe globally.

Details Hidden

Eventide Asset Management is a leader in faith-based on socially responsible investing value-oriented, socially responsible investment manager.The Eventide Fund seeks to provide long-term capital appreciation. It invests primarily in a broad range of equity securities and is not restricted by market-cap. The fund may invest, without limitation, in securities in companies domiciled outside the US either directly or through ADRs. Historically, the fund has had a small/mid-cap growth emphasis. The fund tends to overweight in the healthcare sector.The Eventide Healthcare & Life Sciences Fund is a non-diversified mutual fund investing in the healthcare and life sciences sector. The fund uses bottom-up fundamental research to find companies with the potential to appreciate in value as positive data is released regarding clinical trials and FDA feedback, and market acceptance of products. Under normal market conditions, the fund invests at least 80% of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors.The Eventide Multi-Asset Income Fund seeks current income while maintaining the potential for capital appreciation. The fund has the flexibility to achieve its investment objective by primarily investing in a broad universe of income-producing securities. These securities include debt and equity securities of companies in the U.S. and other markets around the world. These securities may include but are not limited to common stocks, real estate investment trusts (REITs), business development companies, yieldcos, master limited partnerships (MLPs), preferred stocks, corporate bonds, government agency bonds, certificates of deposit, municipal bonds, inflation-linked bonds, mortgage-backed securities, options, exchange traded notes, ETFs, and other investment companies (including mutual funds and closed-end funds). The Fund may invest up to 15% of its net assets in companies whose securities may have legal or contractual restrictions on resale or are otherwise illiquid.The Global Dividends Opportunities Fund Seeks to provide dividend income and long-term capital appreciation with a secondary objective of dividend growth. Is is a globally diversified equity fund representing Eventide's \"best ideas\" approach to dividend-paying stocks. The fund invests globally across industry sectors and market capitalizations through both traditional and non- traditional equity income categories.

Details Hidden

Palo Alto Investors, LLC (PAI) is a leading private investment firm. We make long-term investments for high-net-worth and institutional investors based on original, deep, fundamental research. We don’t rent stocks. We own them. With approximately $900 million in assets under management, we offer a diversified micro cap fund and healthcare sector funds. Significant partner ownership in all of our Funds serves to align our financial interests with the financial interests of our clients. At PAI our mission is to deliver superior returns to our clients by investing for the long term. At the core of our investment philosophy lies the belief that intensive, original research is required to discover and evaluate inefficiently priced equities. We generally focus our investments in micro cap and small cap U.S. equities, which are not closely followed by Wall Street sell-side research firms. We target overlooked, misunderstood and undervalued segments of the equity markets, such as healthcare, energy and technology that have significant potential for appreciation. Our experienced research team has extensive industry experience in the sectors they cover. They utilize a disciplined, bottom-up approach to identify promising investments, and the firm’s investment policies ensure liquidity horizons that are sufficient to take advantage of new opportunities. PAI is committed to providing exemplary client service, maintaining the highest level of ethics, operational excellence and professionalism. PAI is independently owned, and has been registered with the SEC since its inception in 1989

Recent Transactions
Details Hidden

SAGE Therapeutics, Inc. issued USD Common Stock

Details Hidden

SAGE Therapeutics, Inc. issued USD Common Stock

Details Hidden

SAGE Therapeutics, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Transaction Advisors
Escrow Agent

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Clients

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Key Stats and Financials As of 2018
Market Capitalization
$9.14B
Total Enterprise Value
$3.5B
Earnings Per Share
$-8.08
Revenue
$90.3M
Net Profit
$-373M
EBITDA
$-392M
EBITDAMargin
-434.34%
Total Debt
$0
Total Equity
$863M
Enterprise Value Sales
38.72x
TEVNet Income
-9.37x
Debt TEV
0x
Investors
Details Hidden

ARCH Venture Partners focuses on seed and early-stage investments in start-up technology companies, with a particular interest in the life sciences, the physical sciences and information technology. Their life sciences investments focus on biotechnology, pharmaceuticals, medical instrumentation and informatics. Their physical sciences investments focus on companies that are pioneering technology with a range of commercial applications in chemicals/materials, electronics/instrumentation and medical instrumentation industries. The firm's focus within the information technology sector includes electronics/hardware, information, infrastructure/software and commerce. ARCH Venture Partners invests primarily in companies located in the southwestern, Midwestern, eastern seaboard and northwestern sections of the US. The firm exits most of their investments through IPOs or private sales.

Details Hidden

FMR may use a variety of methods of security analysis in managing client assets to select investments including fundamental analysis, quantitative analysis and cyclical analysis. They may also use general macro-economic analysis as a component of its security analysis methods. In addition to relying on public financial statement information, the firm may use extensive corporate visits and interviews with issuer management teams in conducting research. When it comes to the management of the client assets according to the investment objectives, FMR may use a variety of investment strategies including, but not limited to, investing in stocks and other public and private equity securities, bonds and other debt securities of all types and repurchase agreements for those securities, real estate related investments of all types, derivatives, currency spot and forward trading, other investment funds, including exchange traded funds and FMR's or its affiliates' central funds. They may also engage in securities lending to parties such as broker-dealers or other institutions.

Details Hidden

Founder at SAGE Therapeutics, Inc.

Suppliers
Washington University in St. Louis Publishing | St. Louis, MO

The mission of Washington University in St. Louis is the promotion of learning — learning by students and by faculty. Teaching, the transmission of knowledge, is central to our mission, as is research, the creation of new knowledge. Faculty — composed of scholars, scientists, artists and members of the learned professions — serve society by teaching; by adding to the store of human art, creativity, understanding, and wisdom; and by providing direct services, such as health care. The university offers more than 90 programs and almost 1,500 courses leading to bachelor's, master's and doctoral degrees in a broad spectrum of traditional and interdisciplinary fields, with additional opportunities for minor concentrations and individualized programs.

Ligand Pharmaceuticals, Inc. Medical Support Services | LA JOLLA , CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

University of California Investment Services & Portfolio Management

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Competitors
Marinus Pharmaceuticals, Inc. Pharmaceuticals - Radnor, PA

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by SAGE Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of SAGE Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and SAGE Therapeutics, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/sage-therapeutics-inc-1902739
  • https://relationshipscience.com/organization/sage-therapeutics-inc-1902739